Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*
Hospital Universitario Infanta Cristina · Hospital Universitario de Getafe · +11 more institutions
Indexed incrossrefpubmed
Abstract
Objective
To assess the safety and efficacy of the nitric oxide synthase inhibitor 546C88 in patients with septic shock. The predefined primary efficacy objective was survival at day 28.
Design
Multiple-center, randomized, two-stage, double-blind, placebo-controlled, safety and efficacy study.
Setting
A total of 124 intensive care units in Europe, North America, South America, South Africa, and Australasia. PATIENTS: A total of 797 patients with septic shock diagnosed for
Citation impact
921
total citations
- FWCI
- 38.07
- Percentile
- 100%
- References
- 32
Citations per year
Authors
17Topics & keywords
Topics
Keywords
- Medicine
- Septic shock
- Placebo
- Nitric oxide synthase
- Shock (circulatory)
- Double blind
- Nitric oxide
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.